| Autor: |
Dušanka Obradović, Aleksandra Milovančev, Aleksandra Plećaš Đurić, Stanislava Sovilj-Gmizić, Vladimir Đurović, Jovica Šović, Miloš Đurđević, Stevan Tubić, Jelena Bulajić, Milena Mišić, Jovana Jojić, Miroslava Pušara, Ivana Lazić, Mladen Đurković, Renata Bek Pupovac, Aleksandra Vulić, Marija Jozing |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Frontiers in Medicine, Vol 10 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2296-858X |
| DOI: |
10.3389/fmed.2023.1244650 |
| Popis: |
BackgroundHigh-Flow Nasal Cannula (HFNC) oxygen therapy emerged as the therapy of choice in COVID-19-related pneumonia and moderate to severe acute hypoxemic respiratory failure (AHRF). HFNC oxygen therapy in COVID-19 has been recommended based its use to treat AHRF of other etiologies, and studies on assessing outcomes in COVID-19 patients are highly needed. This study aimed to examine outcomes in COVID-19 patients with pneumonia and severe AHRF treated with HFNC.Materials and methodsThe study included 235 COVID-19 patients with pneumonia treated with HFNC. Data extracted from medical records included demographic characteristics, comorbidities, laboratory parameters, clinical and oxygenation status, clinical complications, as well as the length of hospital stay. Patients were segregated into two groups based on their oxygen therapy needs: HDU group, those who exclusively required HFNC and ICU group, those whose oxygen therapy needed to be escalated at some point of hospital stay. The primary outcome was the need for respiratory support escalation (noninvasive or invasive mechanical ventilation) and the secondary outcome was the in-hospital all-cause mortality.ResultsThe primary outcome was met in 113 (48%) of patients. The overall mortality was 70%, significantly higher in the ICU group [102 (90.2%) vs. 62 (50.1%), p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
